Clinical efficacy and safety of immunotherapy after concurrent chemoradiotherapy in advanced esophageal cancer.
- 1Department of Radiation Oncology, Zhejiang Medical & Health Group Quzhou Hospital (Zhejiang Quhua Hospital), Quzhou, 324004, Zhejiang, China.
- 2Department of Radiation Oncology, Zhejiang Medical & Health Group Quzhou Hospital (Zhejiang Quhua Hospital), Quzhou, 324004, Zhejiang, China. [email protected].
Abstract
Purpose
To investigate the efficacy and feasibility of PD-1 antibody combined with concurrent chemoradiotherapy in patients with esophageal cancer.Methods
From July 2020 to October 2023, 15 patients with esophageal cancer in Zhejiang Quhua Hospital were treated with PD-1 monoclonal antibody after concurrent chemoradiotherapy. The incidence of adverse reactions was recorded throughout the treatment period. The Kaplan-Meier survival analysis was used to estimate median overall survival (OS) and progression-free survival (PFS).Results
All 15 patients were enrolled, with a median follow-up of 23.0 months (ranging from 6.0 to 37.5 months). The 1-year OS rate was 93.3%, and the 2-year OS rate was 46.7%. No treatment-related deaths were reported.Conclusion
Concurrent chemoradiotherapy combined with PD-1 antibody yielded encouraging survival outcomes in patients with esophageal cancer, and this regimen deserves further clinical exploration.
Related
- Efficacy and safety analysis of consolidation immunotherapy following definitive concurrent chemoradiotherapy for locally advanced esophageal squamous cell carcinoma
- A Systematic Review and Meta-Analysis: Does Molecular Hydrogen Exert Radioprotective Effects Without Compromising the Antitumor Efficacy of Radiotherapy or Concurrent Chemoradiotherapy?
- Induction Chemoimmunotherapy Versus Induction Chemotherapy Followed by Concurrent Chemoradiotherapy for Locally Advanced Esophageal Squamous Cell Carcinoma: A Propensity Score-Matched Study
- Consolidation immunotherapy after concurrent chemoradiotherapy enabling conversion surgery for stage IIIB pulmonary NUT carcinoma: a case report and literature review
- Efficacy comparison of neoadjuvant chemotherapy, chemoradiotherapy, and chemoimmunotherapy in resectable esophageal squamous cell carcinoma: short- and long-term outcomes from a propensity score-matched analysis
BibTeX
@article{hu2026clinical,
title = {{Clinical efficacy and safety of immunotherapy after concurrent chemoradiotherapy in advanced esophageal cancer.}},
author = {Chunxiu Hu and Yi Liu and Zhengqi Yang and Qin Chen and Yuefang Tong and Bin Da and Yuefei Sun and Huiting Rao},
journal = {Journal of cardiothoracic surgery},
year = {2026},
month = jul,
doi = {10.1186/s13019-026-04502-1},
url = {https://europepmc.org/article/MED/42894226},
note = {CC BY-NC-ND},
}
RIS
TY - JOUR
TI - Clinical efficacy and safety of immunotherapy after concurrent chemoradiotherapy in advanced esophageal cancer.
AU - Chunxiu Hu
AU - Yi Liu
AU - Zhengqi Yang
AU - Qin Chen
AU - Yuefang Tong
AU - Bin Da
AU - Yuefei Sun
AU - Huiting Rao
PY - 2026
DA - 2026/07/01
JO - Journal of cardiothoracic surgery
DO - 10.1186/s13019-026-04502-1
UR - https://europepmc.org/article/MED/42894226
AB - Purpose To investigate the efficacy and feasibility of PD-1 antibody combined with concurrent chemoradiotherapy in patients with esophageal cancer.Methods From July 2020 to October 2023, 15 patients with esophageal cancer in Zhejiang Quhua Hospital were treated with PD-1 monoclonal antibody after concurrent chemoradiotherapy. The incidence of adverse reactions was recorded throughout the treatment period. The Kaplan-Meier survival analysis was used to estimate median overall survival (OS) and progression-free survival (PFS).Results All 15 patients were enrolled, with a median follow-up of 23.0 months (ranging from 6.0 to 37.5 months). The 1-year OS rate was 93.3%, and the 2-year OS rate was 46.7%. No treatment-related deaths were reported.Conclusion Concurrent chemoradiotherapy combined with PD-1 antibody yielded encouraging survival outcomes in patients with esophageal cancer, and this regimen deserves further clinical exploration.
SN - 1749-8090
ER -